Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for liver and viral diseases. Founded in 2018, the company's mission is to become a leader in these therapeutic areas by improving patient outcomes through best-in-class therapies. Its headquarters are located in South San Francisco, California.

Aligos Therapeutics focuses on addressing significant unmet medical needs in chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), obesity, and coronavirus infections. The company leverages proprietary oligonucleotide and small molecule platforms to advance its pipeline. Key drug candidates include pevifoscorvir sodium (formerly ALG-000184), an oral small molecule capsid assembly modulator (CAM-E) in Phase 2 development for chronic HBV, and ALG-055009, an oral small molecule thyroid hormone receptor beta (THR-β) agonist in Phase 1/2 studies for MASH and obesity. Other programs include ALG-097558 for coronavirus infections and ALG-125755 (siRNA) for chronic HBV.

Dr. Lawrence M. Blatt, Ph.D., MBA, serves as the Chairman, President, and Chief Executive Officer, a role he has held since February 2018. Recent notable developments include an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd. for pevifoscorvir sodium in Greater China, which includes a $25 million upfront payment and potential milestones. The company also received FDA Fast Track Designation for pevifoscorvir sodium for chronic HBV. As a clinical-stage company, Aligos Therapeutics currently has no commercial products and faces ongoing financial challenges, with its cash runway extending into Q3 2026 as reported in March 2026.